OVERVIEW

The Lung Cancer Clinical Masterclass Series is organized by Clinical CME Group, LLC and will be held from Aug 01, 2024 - Aug 31, 2025.

Series Title and Episodes:

Surgically resectable disease - (Episode 1 – August 2024)
Locally advanced NSCLC - (Episode 2 – September 2024)
EGFR-mutant lung cancer - (Episode 3 – October 2024)
Novel stratergies in 2nd line and beyond NSCLC - (Episode 4 – November 2024)
Small cell lung cancer – extensive (ES) and Limited (LS) - (Episode 5 – December 2025)
Oncogenic fusions in lung cancer - (Episode 6 – January 2025)
KRAS mutant lung cancers - (Episode 7 – February 2025)
Blood-based detection and monitoring in lung CA - (Episode 8 – March 2025)
New frontiers in lung cancer radiation therapy - (Episode 9 – April 2025)
Lung cancer immunotherapy: Today - (Episode 10 – May 2025)
Lung cancer immunotherapy: Tomorrow - (Episode 11 – June 2025)
Lung cancer screening and early detection - (Episode 12 – July 2025)
Mesothelioma - (Episode 13 – August 2025)

Description:
The masterclass will examine the screening and diagnosis of early-stage lung cancer, investigate different histological techniques and the use of genomics for improved detection, classification, and monitoring. The series will also feature discussions around oncogenic driver mutations and their potential as targets for the development of molecular treatments. Existing and new treatment strategies will be appraised including research and developments in surgery, immunotherapy, chemotherapy, and radiation therapy in lung cancer in general and more specifically in non-small cell lung cancer (NSCLC). The last episode will discuss the management of mesothelioma.

Learning Objectives

Examine the pathway for the diagnosis and screening of SCLC and NSCLC
Discuss the role of novel therapies and treatment regimens in the management of lung cancer including:
- The translation of data from the study of specific genes into potential novel treatment regimens such as EGFR, KRAS, ALK, ROS-1, NTRK, RET and MET
- The development of new therapies and best practices in the management of first-line and second-line treatment
Review effective radiotherapy schedules to improve patient outcomes
Review surgically resectable disease in the neo-adjuvant and peri-operative setting

KEY DATES

01 Aug, 2024

Event Start Date

31 Aug, 2025

Event End Date

ACCREDITATION & CREDITS

Accreditation:
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Clinical CME Group, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 13 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses:
Credit being awarded: 13 ANCC contact hours.
Pharmacists:
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 13 contact hours.
Physician Associate:
KH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13 AAPA Category 1 CME credits. Approval is valid until Expiration Date. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners:
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Clinical CME Group, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 13 contact hour(s) (which includes 9 hour(s) of pharmacology).

13 AMA PRA Category 1 Credits™

13 Contact Hours

13 AAPA

9 Hours

TARGET AUDIENCE

PhysicianPharmacistPhysician AssistantOncologistsHealthcare ProfessionalsResidentsNursesPulmonologistsNurse PractitionersFellowsThoracic SurgeonsOther Health Professionals